Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D

June 24, 2018 7:17 pm

The Boehringer Ingelheim representative discusses how the future of empagliflozin research should shape out.

Category: News
About The Author
-
Previous

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease
Next

Reversing T2D with a keto diet — Diet Doctor Podcast with Dr. Sarah Hallberg

Related Videos

Hua-Medicine-A-Global-Effort-to-Stop-Diabetes

Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes

PILA-PHARMA

PILA PHARMA

Low-carb-for-diabetes-A-transformation-Diet-Doctor-Podcast

Low carb for diabetes: A transformation — Diet Doctor Podcast

Dr.-David-Unwin-The-Glycaemic-Index-Helping-Patients-in-Primary-care-with-T2D

Dr. David Unwin – ‘The Glycaemic Index: Helping Patients in Primary care with T2D’

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

Type-2-Diabetes-Treatments-1

A Data Integration Multi-Omics Approach to Study Calorie Restriction-Induced Changes in Insulin Sensitivity